HC Wainwright & Co. Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $120

HC Wainwright & Co. analyst Mitchell S. Kapoor has maintained a Buy rating on Ionis Pharmaceuticals (NASDAQ: IONS) and raised the price target from $110 to $120. This adjustment reflects a positive outlook for the company's stock performance.